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Sir,
We earlier reported in this journal results from an explorative
pharmacogenetic study for the efficacy of second-line treatment of
oxaliplatin combined with capecitabine of advanced colorectal
cancer (ACC) (Kweekel et al, 2009). These results were obtained
using a DNA repair array (Asper Biotech, Tartu, Estonia) to
identify novel single nucleotide polymorphisms (SNPs) that are
associated with progression-free survival (PFS) for oxaliplatin/
capecitabine combination therapy (Koopman et al, 2007). After
correction for multiple testing for five DNA repair pathways
investigated, SNPs in the genes encoding ataxia telangiectasia
mutated (ATM rs1801516) and excision repair cross-complement-
ing group 5 (ERCC5 rs1047768) were significantly associated with
PFS in the final multivariate analysis.
Owing to the explorative nature of the study, we concluded that
confirmation was required in a separate cohort of oxaliplatin/
capecitabine-treated patients. We, therefore, tested the associa-
tions of the same SNPs in the ATM and ERCC5 genes with PFS in
patients treated in another cohort – the CAIRO2 study. Blood
samples were available of 560 patients who were treated with
oxaliplatin combined with capecitabine and bevacizumab, with or
without cetuximab, as first-line treatment of ACC (Tol et al, 2009).
Germline DNA was isolated from peripheral white blood cells by
the standard manual salting-out method. We genotyped the ATM
and ERCC5 polymorphisms using a Taqman 7500 (Applied
Biosystems, Foster City, CA, USA) with pre-designed assays
according to the manufacturer’s protocol. Negative controls
(water) were included. The collection of blood samples for
pharmacogenetic research was approved by the local institutional
review boards of all participating centres, and all patients gave
written informed consent.
The genotype frequencies in the CAIRO2 patients were not
significantly different from the earlier study (P¼0.38 and P¼0.68
for ATM and ERCC5, respectively), and were in Hardy–Weinberg
equilibrium. However, the frequency of ATM homozygote
mutants was 1.6% in the CAIRO2 patients vs 4.4% in patients in
the earlier study.
The results for the associations with PFS are shown in Table 1.
As opposed to our initial observation, the ATM and ERCC5
polymorphisms were not significantly associated with PFS in the
CAIRO2 patients.
Several reasons could underlie the lack of replication of
association. First, our initial results (Kweekel et al, 2009) may
have been false positive findings. Even though we had corrected for
multiple testing, this approach may have been ineffective to correct
for false positives. On the other hand, the frequency of ATM
homozygote mutant patients in the CAIRO2 was lower than in the
earlier study, which could have impacted the power to detect
the association. However, the HR for PFS was 4.25 (95% CI,
1.45–12.44; homozygote mutants vs wild type) in our initial study,
whereas it was 0.90 (95% CI, 0.37–2.18) in the CAIRO2 patients,
indicating lack of association regardless of genotype frequency.
Second, our initial findings were derived from patients receiving
second-line therapy of oxaliplatin combined with capecitabine,
whereas CAIRO2 concerns data from first-line therapy with the
addition of bevacizumab and cetuximab also. We also recently
reported an opposite association of the FCGR3A Phe158Val
polymorphism with PFS for cetuximab in the first-line setting
for ACC compared with results from third-line settings (Pander
et al, 2010). As the DNA repair array should theoretically be
applicable to any platinum-containing regimen, this explanation is
less likely for the present finding.
Finally, it is possible that the addition of cetuximab could have
negatively influenced the efficacy of oxaliplatin in the cetuximab
arm in the CAIRO2 study (Dahan et al, 2009; Punt and Tol, 2009),
which may have obscured the associations when both treatment
arms were combined for analysis. However, the outcome of our
analysis did not change when we restricted this to patients treated
without cetuximab in the CAIRO2 study (data not shown).
We, therefore, conclude that the ATM and ERCC5 SNPs have no
relevant impact on the PFS of oxaliplatin-based therapy for ACC.
The negative result of this study underlines the importance
of validating and reporting the findings from retrospective
explorative studies (Koopman et al, 2009). *Correspondence: Dr H-J Guchelaar; E-mail: h.j.guchelaar@lumc.nl
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Table 1 Associations of ATM (rs1801516) and ERCC5 (rs1047768) polymorphisms with PFS
n Median PFS in months (95% CI) Univariate HR (95% CI)
a P




Wild type 371 9.1 (8.3–10.4) 1 — 1 —
Heterozygote 127 12.4 (9.6–13.5) 0.88 (0.70–1.09) 0.245 0.93 (0.75–1.17) 0.543
Homozygote mutant 8 11.8 (7.2-N)
c 0.61 (0.27–1.36) 0.225 0.94 (0.42–2.12) 0.881
ERCC5 rs1047768
Wild type 180 10.6 (9.1–12.5) 1 — 1 —
Heterozygote 267 9.2 (8.2–10.6) 1.13 (0.93–1.39) 0.227 1.15 (0.93–1.42) 0.194
Homozygote mutant 77 10.1 (8.5–12.2) 0.96 (0.72–1.29) 0.797 0.94 (0.69–1.28) 0.689
Abbreviations: ATM¼ataxia telangiectasia mutated; CI¼confidence interval; ERCC5¼excision repair cross-complementing group 5; HR¼hazard ratios; PFS¼progression-
free survival.
aHR, 95% CI and P-values computed using a Cox proportional hazards model with the wild type as reference.
bCovariates included in the multivariate model:
age, gender, serum LDH (normal vs above normal) and treatment arm (oxaliplatin, capecitabine and bevacizumab vs oxaliplatin, capecitabine, bevacizumab and cetuximab).
cThe upper limit of the 95% CI for PFS of the ATM homozygote mutants could not be estimated because of the low number of patients.
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